Free Trial

Evaxion A/S (EVAX) Competitors

Evaxion A/S logo
$2.74 -0.03 (-1.08%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$2.74 +0.00 (+0.18%)
As of 11/13/2026 06:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

EVAX vs. KZIA, EQ, GNLX, TNYA, and CBUS

Should you buy Evaxion A/S stock or one of its competitors? Evaxion A/S's main competitors and comparable companies include Novogen (KZIA), Equillium (EQ), Genelux (GNLX), Tenaya Therapeutics (TNYA), and Cibus (CBUS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Evaxion A/S compare to Novogen?

Novogen (NASDAQ:KZIA) and Evaxion A/S (NASDAQ:EVAX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, media sentiment, risk, profitability, valuation and earnings.

Novogen presently has a consensus target price of $29.50, suggesting a potential upside of 345.62%. Evaxion A/S has a consensus target price of $11.25, suggesting a potential upside of 310.58%. Given Novogen's stronger consensus rating and higher possible upside, equities research analysts clearly believe Novogen is more favorable than Evaxion A/S.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Novogen
1 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.78
Evaxion A/S
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60

30.9% of Novogen shares are owned by institutional investors. Comparatively, 11.0% of Evaxion A/S shares are owned by institutional investors. 1.0% of Novogen shares are owned by company insiders. Comparatively, 41.6% of Evaxion A/S shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Evaxion A/S had 3 more articles in the media than Novogen. MarketBeat recorded 6 mentions for Evaxion A/S and 3 mentions for Novogen. Novogen's average media sentiment score of 0.42 beat Evaxion A/S's score of 0.21 indicating that Novogen is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Novogen
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Evaxion A/S
0 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Novogen's return on equity of 0.00% beat Evaxion A/S's return on equity.

Company Net Margins Return on Equity Return on Assets
NovogenN/A N/A N/A
Evaxion A/S N/A -61.43%-34.23%

Novogen has a beta of 2.34, meaning that its stock price is 134% more volatile than the broader market. Comparatively, Evaxion A/S has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market.

Evaxion A/S has higher revenue and earnings than Novogen.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novogen$1.23M69.81-$13.41MN/AN/A
Evaxion A/S$7.53M3.28-$7.71M-$1.21N/A

Summary

Novogen beats Evaxion A/S on 9 of the 13 factors compared between the two stocks.

How does Evaxion A/S compare to Equillium?

Evaxion A/S (NASDAQ:EVAX) and Equillium (NASDAQ:EQ) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

Equillium's return on equity of -37.33% beat Evaxion A/S's return on equity.

Company Net Margins Return on Equity Return on Assets
Evaxion A/SN/A -61.43% -34.23%
Equillium N/A -37.33%-35.07%

Evaxion A/S currently has a consensus target price of $11.25, indicating a potential upside of 310.58%. Equillium has a consensus target price of $7.13, indicating a potential upside of 452.33%. Given Equillium's stronger consensus rating and higher possible upside, analysts plainly believe Equillium is more favorable than Evaxion A/S.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Evaxion A/S
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60
Equillium
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
2 Strong Buy rating(s)
2.92

11.0% of Evaxion A/S shares are owned by institutional investors. Comparatively, 27.0% of Equillium shares are owned by institutional investors. 41.6% of Evaxion A/S shares are owned by company insiders. Comparatively, 17.8% of Equillium shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Evaxion A/S has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market. Comparatively, Equillium has a beta of 2.08, meaning that its stock price is 108% more volatile than the broader market.

Evaxion A/S has higher revenue and earnings than Equillium. Equillium is trading at a lower price-to-earnings ratio than Evaxion A/S, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evaxion A/S$7.53M3.28-$7.71M-$1.21N/A
EquilliumN/AN/A-$22.40M-$0.18N/A

In the previous week, Evaxion A/S had 1 more articles in the media than Equillium. MarketBeat recorded 6 mentions for Evaxion A/S and 5 mentions for Equillium. Equillium's average media sentiment score of 0.84 beat Evaxion A/S's score of 0.21 indicating that Equillium is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Evaxion A/S
0 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Equillium
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Equillium beats Evaxion A/S on 9 of the 15 factors compared between the two stocks.

How does Evaxion A/S compare to Genelux?

Genelux (NASDAQ:GNLX) and Evaxion A/S (NASDAQ:EVAX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations, institutional ownership and media sentiment.

Genelux has a beta of 0.68, suggesting that its share price is 32% less volatile than the broader market. Comparatively, Evaxion A/S has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market.

In the previous week, Evaxion A/S had 5 more articles in the media than Genelux. MarketBeat recorded 6 mentions for Evaxion A/S and 1 mentions for Genelux. Genelux's average media sentiment score of 1.82 beat Evaxion A/S's score of 0.21 indicating that Genelux is being referred to more favorably in the media.

Company Overall Sentiment
Genelux Very Positive
Evaxion A/S Neutral

37.3% of Genelux shares are owned by institutional investors. Comparatively, 11.0% of Evaxion A/S shares are owned by institutional investors. 7.5% of Genelux shares are owned by insiders. Comparatively, 41.6% of Evaxion A/S shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Evaxion A/S's return on equity of -61.43% beat Genelux's return on equity.

Company Net Margins Return on Equity Return on Assets
GeneluxN/A -205.85% -138.79%
Evaxion A/S N/A -61.43%-34.23%

Genelux currently has a consensus price target of $20.00, indicating a potential upside of 972.39%. Evaxion A/S has a consensus price target of $11.25, indicating a potential upside of 310.58%. Given Genelux's stronger consensus rating and higher probable upside, research analysts clearly believe Genelux is more favorable than Evaxion A/S.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Genelux
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.75
Evaxion A/S
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60

Evaxion A/S has higher revenue and earnings than Genelux. Evaxion A/S is trading at a lower price-to-earnings ratio than Genelux, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genelux$10K8,437.26-$32.15M-$0.86N/A
Evaxion A/S$7.53M3.28-$7.71M-$1.21N/A

Summary

Genelux beats Evaxion A/S on 9 of the 16 factors compared between the two stocks.

How does Evaxion A/S compare to Tenaya Therapeutics?

Tenaya Therapeutics (NASDAQ:TNYA) and Evaxion A/S (NASDAQ:EVAX) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

Tenaya Therapeutics has a beta of 2.88, suggesting that its stock price is 188% more volatile than the broader market. Comparatively, Evaxion A/S has a beta of 0.61, suggesting that its stock price is 39% less volatile than the broader market.

Evaxion A/S's return on equity of -61.43% beat Tenaya Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Tenaya TherapeuticsN/A -88.96% -69.51%
Evaxion A/S N/A -61.43%-34.23%

90.5% of Tenaya Therapeutics shares are owned by institutional investors. Comparatively, 11.0% of Evaxion A/S shares are owned by institutional investors. 2.7% of Tenaya Therapeutics shares are owned by company insiders. Comparatively, 41.6% of Evaxion A/S shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Evaxion A/S has higher revenue and earnings than Tenaya Therapeutics. Evaxion A/S is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tenaya TherapeuticsN/AN/A-$90.60M-$0.49N/A
Evaxion A/S$7.53M3.28-$7.71M-$1.21N/A

Tenaya Therapeutics presently has a consensus target price of $4.00, indicating a potential upside of 1,045.48%. Evaxion A/S has a consensus target price of $11.25, indicating a potential upside of 310.58%. Given Tenaya Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Tenaya Therapeutics is more favorable than Evaxion A/S.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tenaya Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86
Evaxion A/S
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60

In the previous week, Evaxion A/S had 3 more articles in the media than Tenaya Therapeutics. MarketBeat recorded 6 mentions for Evaxion A/S and 3 mentions for Tenaya Therapeutics. Tenaya Therapeutics' average media sentiment score of 1.13 beat Evaxion A/S's score of 0.21 indicating that Tenaya Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Tenaya Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Evaxion A/S
0 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Tenaya Therapeutics beats Evaxion A/S on 9 of the 15 factors compared between the two stocks.

How does Evaxion A/S compare to Cibus?

Cibus (NASDAQ:CBUS) and Evaxion A/S (NASDAQ:EVAX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

Cibus currently has a consensus price target of $9.00, indicating a potential upside of 696.46%. Evaxion A/S has a consensus price target of $11.25, indicating a potential upside of 310.58%. Given Cibus' higher possible upside, analysts clearly believe Cibus is more favorable than Evaxion A/S.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cibus
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Evaxion A/S
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60

Evaxion A/S has higher revenue and earnings than Cibus. Evaxion A/S is trading at a lower price-to-earnings ratio than Cibus, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cibus$3.64M23.73-$127.08M-$1.50N/A
Evaxion A/S$7.53M3.28-$7.71M-$1.21N/A

In the previous week, Cibus had 4 more articles in the media than Evaxion A/S. MarketBeat recorded 10 mentions for Cibus and 6 mentions for Evaxion A/S. Evaxion A/S's average media sentiment score of 0.21 beat Cibus' score of -0.43 indicating that Evaxion A/S is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cibus
0 Very Positive mention(s)
0 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Evaxion A/S
0 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

33.8% of Cibus shares are owned by institutional investors. Comparatively, 11.0% of Evaxion A/S shares are owned by institutional investors. 29.9% of Cibus shares are owned by insiders. Comparatively, 41.6% of Evaxion A/S shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Evaxion A/S has a net margin of 0.00% compared to Cibus' net margin of -2,131.38%. Evaxion A/S's return on equity of -61.43% beat Cibus' return on equity.

Company Net Margins Return on Equity Return on Assets
Cibus-2,131.38% -526.66% -28.12%
Evaxion A/S N/A -61.43%-34.23%

Cibus has a beta of 1.65, suggesting that its share price is 65% more volatile than the broader market. Comparatively, Evaxion A/S has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market.

Summary

Evaxion A/S beats Cibus on 9 of the 15 factors compared between the two stocks.

Get Evaxion A/S News Delivered to You Automatically

Sign up to receive the latest news and ratings for EVAX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EVAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EVAX vs. The Competition

MetricEvaxion A/SBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$24.72M$4.13B$7.89B$12.09B
Dividend YieldN/A3.64%2.47%4.54%
P/E Ratio-2.2626.9533.2628.22
Price / Sales3.2816.388.685.82
Price / CashN/A21.8921.0222.32
Price / Book1.344.504.803.95
Net Income-$7.71M-$24.19M$3.52B$391.78M
7 Day Performance-8.67%-2.82%-1.52%-0.34%
1 Month Performance-2.14%-5.39%-3.54%-5.79%
1 Year Performance-49.82%-1.71%1.45%-5.71%

Evaxion A/S Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EVAX
Evaxion A/S
2.6707 of 5 stars
$2.74
-1.1%
$11.25
+310.6%
N/A$24.72M$7.53MN/A46
KZIA
Novogen
3.8681 of 5 stars
$7.40
-0.1%
$29.50
+298.6%
N/A$96.10M$1.23MN/A6
EQ
Equillium
2.8529 of 5 stars
$1.46
-3.0%
$7.57
+420.4%
N/A$95.11M$41.10MN/A14
GNLX
Genelux
3.2642 of 5 stars
$1.95
-5.8%
$20.00
+925.6%
N/A$93.66M$10KN/A26
TNYA
Tenaya Therapeutics
2.9134 of 5 stars
$0.37
-5.9%
$4.00
+979.3%
N/A$89.80MN/AN/A70

Related Companies and Tools


This page (NASDAQ:EVAX) was last updated on 11/15/2026 by MarketBeat.com Staff.
From Our Partners